{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:22:58Z","timestamp":1793380978483,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["20234Z0002"],"award-info":[{"award-number":["20234Z0002"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470213"],"award-info":[{"award-number":["82470213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170206"],"award-info":[{"award-number":["82170206"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000156"],"award-info":[{"award-number":["82000156"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015796","name":"Shanghai Lingjun Program","doi-asserted-by":"publisher","award":["20YF1439700"],"award-info":[{"award-number":["20YF1439700"]}],"id":[{"id":"10.13039\/100015796","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC2502600"],"award-info":[{"award-number":["2022YFC2502600"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.exphem.2025.104859","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:22:29Z","timestamp":1752679349000},"page":"104859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Impaired CMV-specific CD4+ T-cell reconstitution is associated with CMV infection after letermovir cessation"],"prefix":"10.1016","volume":"150","author":[{"given":"Luxiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengkai","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhe","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2025.104859_bib0001","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104859_bib0002","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.exphem.2025.104859_bib0003","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fmicb.2019.01186","article-title":"Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients","volume":"10","author":"Stern","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.exphem.2025.104859_bib0004","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood.V90.6.2502","article-title":"Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome","volume":"90","author":"Salzberger","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104859_bib0005","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2025.104859_bib0006","doi-asserted-by":"crossref","first-page":"510.e1","DOI":"10.1016\/j.jtct.2022.05.020","article-title":"Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-related mortality","volume":"28","author":"Liu","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.exphem.2025.104859_bib0007","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.exphem.2025.104859_bib0008","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1093\/cid\/ciz1210","article-title":"Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.exphem.2025.104859_bib0009","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3324\/haematol.2022.280685","article-title":"Cytomegalovirus-specific T cells restricted for shared and donor human leukocyte antigens differentially impact on cytomegalovirus reactivation risk after allogeneic hematopoietic stem cell transplantation","volume":"108","author":"Tassi","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2025.104859_bib0010","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/infdis\/jiy592","article-title":"The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients","volume":"219","author":"El Haddad","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.exphem.2025.104859_bib0011","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jinf.2016.04.033","article-title":"Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation","volume":"73","author":"Liu","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.exphem.2025.104859_bib0012","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cyto.b.20420","article-title":"Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations","volume":"74","author":"Gratama","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.exphem.2025.104859_bib0013","doi-asserted-by":"crossref","first-page":"ofad386","DOI":"10.1093\/ofid\/ofad386","article-title":"Impact of baseline and week 2 and week 4 posttransplant CMV cell-mediated immunity on risk of CMV infections and mortality in recipients of allogeneic hematopoietic cell transplant","volume":"10","author":"Ariza-Heredia","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.exphem.2025.104859_bib0014","doi-asserted-by":"crossref","first-page":"392.e1","DOI":"10.1016\/j.jtct.2023.03.018","article-title":"Immunologic monitoring after allogeneic stem cell transplantation: T-SPOT.CMV and QuantiFERON-CMV, are they the same?","volume":"29","author":"Callens","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.exphem.2025.104859_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e16792","article-title":"Interferon-gamma FlowSpot assay for the measurement of the T-cell response to cytomegalovirus","volume":"9","author":"Ye","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.exphem.2025.104859_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13220","article-title":"Quantiferon-cytomegalovirus assay: a potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients","volume":"22","author":"Paouri","year":"2018","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.exphem.2025.104859_bib0017","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/bloodadvances.2023012008","article-title":"Impaired T cells and \u201cmemory-like\u201d NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation","volume":"8","author":"Lauruschkat","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.104859_bib0018","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41409-020-01047-2","volume":"56","author":"XXu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104859_bib0019","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1016\/j.scib.2021.06.002","article-title":"Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial","volume":"66","author":"Wang","year":"2021","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.exphem.2025.104859_bib0020","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/s41409-022-01639-0","article-title":"Cladribine-based debulking chemotherapy sequential with reduced intensity regimen and post-transplantation maintenance for refractory myeloid leukemia: a prospective phase II clinical trial","volume":"57","author":"Wang","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104859_bib0021","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/s41375-023-01962-5","article-title":"Correction: \u201cThe 5th edition of The World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms\u201d Leukemia. 2022;36:1720\u20131748","volume":"37","author":"Alaggio","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.104859_bib0022","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2025.104859_bib0023","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.exphem.2025.104859_bib0024","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2025.104859_bib0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/CMR.00034-08","article-title":"Immunobiology of human cytomegalovirus: from bench to bedside","volume":"22","author":"Crough","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.exphem.2025.104859_bib0026","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104859_bib0027","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.exphem.2025.104859_bib0028","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M","article-title":"Non-parametric inference for cumulative incidence functions in competing risks studies","volume":"16","author":"Lin","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.exphem.2025.104859_bib0029","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood-2018-10-878918","article-title":"Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation","volume":"133","author":"Camargo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104859_bib0030","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ajh.26094","article-title":"Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution","volume":"96","author":"Leserer","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2025.104859_bib0031","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3390\/v15112213","article-title":"Cytomegalovirus-specific T cells in pediatric liver transplant recipients","volume":"15","author":"Getsuwan","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.exphem.2025.104859_bib0032","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fcimb.2020.00202","article-title":"The CD4+ T cell response to human cytomegalovirus in healthy and immunocompromised people","volume":"10","author":"Lim","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.exphem.2025.104859_bib0033","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41409-020-01178-6","article-title":"Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study","volume":"56","author":"Beauvais","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104859_bib0034","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/bloodadvances.2022008667","article-title":"The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients","volume":"7","author":"Sourisseau","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.104859_bib0035","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.bbmt.2017.11.038","article-title":"Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients","volume":"24","author":"Camargo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2025.104859_bib0036","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104859_bib0037","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.exphem.2025.104859_bib0038","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1182\/bloodadvances.2022008047","article-title":"Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults","volume":"6","author":"Politikos","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.104859_bib0039","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10238-023-01270-3","article-title":"Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Huang","year":"2024","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.exphem.2025.104859_bib0040","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/bloodadvances.2022009376","article-title":"CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia","volume":"7","author":"Akahoshi","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.104859_bib0041","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.104859_bib0042","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/bloodadvances.2021005509","article-title":"Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG","volume":"6","author":"Turki","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.104859_bib0043","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41423-023-01046-5","article-title":"Expanded clinical-grade NK cells exhibit stronger effects than primary NK cells against HCMV infection","volume":"20","author":"Shang","year":"2023","journal-title":"Cell Mol Immunol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2500150X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2500150X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:17:18Z","timestamp":1783437438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X2500150X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":43,"alternative-id":["S0301472X2500150X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2025.104859","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impaired CMV-specific CD4+ T-cell reconstitution is associated with CMV infection after letermovir cessation","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2025.104859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Experimental Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104859"}}